This paper studies a variant of the McEliece cryptosystem able to ensure that the code used as the public key is no longer permutationequivalent to the secret code. This increases the security level of the public key, thus opening the way for reconsidering the adoption of classical families of codes, like Reed-Solomon codes, that have been longly excluded from the McEliece cryptosystem for security reasons. It is well known that codes of these classes are able to yield a reduction in the key size or, equivalently, an increased level of security against information set decoding; so, these are the main advantages of the proposed solution. We also describe possible vulnerabilities and attacks related to the considered system, and show what design choices are best suited to avoid them.

In this paper, we address the problem of achieving efficient code-based digital signatures with small public keys. The solution we propose exploits sparse syndromes and randomly designed low-density generator matrix codes. Based on our evaluations, the proposed scheme is able to outperform existing solutions, permitting to achieve considerable security levels with very small public keys.

Objective Femoroacetabular impingement (FAI) is a condition that has been increasingly recognized as a source of hip pain and a possible risk factor to early development of hip osteoarthritis (OA). To our knowledge, the use of HA in the treatment of femoroacetabular FAI has been investigated only by two studies, both using a high molecular weight HA. The aim of this study was to evaluate the efficacy of two weekly injections of an hexadecylamide derivative of HA (HYADD4-G, HYMOVIS, Fidia Farmaceutici) in FAI. Methods All patients received two weekly intra-articular injections of Hymovis at baseline and after 7 days. Clinical and functional assessments were performed at baseline and was repeated after 1, 3, 6 and 12 months. Functional measures included visual analogue scale (VAS) for pain, Harris Hip score (HHS), Lequesne Index (LI), Tegner activity level scale (TALS) and monthly consumption of nonsteroidal anti-inflammatory drugs (NSAIDs). Results Twenty-one hips (19 patients, 2 bilateral cases) were treated. The variables VAS, HHS as well as Lequesne improved significantly from T0 to T4 (at 12 months) with the best improvement between T0 and T1. At the same time, a reduction in NSAIDs monthly intake was registered. On the other hand, a significant improvement in Tegner scale was not observed. No adverse events were registered. Conclusion This study states that one cycle of HYADD4-G could be a safe and effective treatment in patients with FAI, showing significative results in term of pain control as well as hip functionality and quality of life up to 1 year.

No abstract

No abstract